A comparative study of transurethral 450 nm DiLVP and 1470 nm DiLEP in the treatment of benign prostatic hyperplasia.

To compare the clinical effects of 450 nm diode laser vaporisation of the prostate (450 nm DiLVP) and 1470 nm diode laser enucleation of the prostate (1470 nm DiLEP) in the surgical treatment of benign prostate hyperplasia (BPH). BPH patients who were treated with 450 nm DiLVP or 1470 nm DiLEP in the Department of Urology of Jinan Central Hospital from November in 2021 to November in 2023 were selected for retrospective analysis. The assessment indexes included: (1) Preoperative general information; (2) Perioperative indicators; (3) Postoperative follow-up indicators(followed up at 1 and 3 months after surgery). A total of 128 BPH patients were included in the study, 63 in the experimental group with 450 nm DiLVP and 65 in the control group with 1470 nm DiLEP. There was no significant difference in the baseline information between the two groups (P > 0.05). Compared with the 1470 nm DiLEP group, the operation time, the laser energy consumption and bladder irrigation time were significantly reduced in the 450 nm DiLVP group (P < 0.001). At 3 months postoperatively, Qmax relief was significant in the 1470 nm DiLEP group (P = 0.023). (1) Perioperatively, compared with the 1470 nm DiLEP, 450 nm DiLVP has shorter operation time, irrigation time, and laser energy consumption; (2)Postoperative follow-up: 450 nm DiLVP and 1470 nm DiLEP have similar efficacy in improving BPH symptoms; 1470 nm DiLEP may have greater impact on max urinary flow rate in long-tem follow-up, which needs further verification.